• Eyedrops are larger than needed, and pharmaceutical companies know it.
• Research has shown it’s possible to waste less — and that smaller eyedrops work just as well.
• A “micro drop” never made it to market, possibly because it raised too many questions about profits.
• Like eyedrops, cancer drugs are sold by volume, so they're vulnerable to the same problem.
• Paying for wasted drugs adds to the cost of health care that patients are already bearing.

Read the original article on ProPublica. Copyright 2017. Follow ProPublica on Twitter.